‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field

Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior CEO Claudia Ulbrich.